Regorafenib versus TAS-102 as Salvage-line in patients with colorectal cancer refractory to standard chemotherapies: a multicenter observational study

Trial Profile

Regorafenib versus TAS-102 as Salvage-line in patients with colorectal cancer refractory to standard chemotherapies: a multicenter observational study

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Jul 2017

At a glance

  • Drugs Regorafenib (Primary) ; Tipiracil/trifluridine (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms REGOTAS
  • Most Recent Events

    • 04 Jul 2017 Status changed from recruiting to completed.
    • 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 02 Jan 2017 Planned End Date changed from 30 Jun 2017 to 30 Sep 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top